HANSA BIOPHARMA

Investor Call

H.C. Andersen Capital
Commercial progress and launch strategy
October 27, 2022

Pierre-Henri Patin
VP Commercial Operations

Forward-looking statements

This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occur in the future. Some of these forward-looking statements, by their nature, could have an impact on Hansa Biopharma's business, financial condition and results of operations [or that of its parent, affiliate, or subsidiary companies]. Terms such as "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those projected, whether expressly or impliedly, in a forward-looking statement or affect the extent to which a particular projection is realized. Such factors may include, but are not limited to, changes in implementation of Hansa Biopharma's strategy and its ability to further grow; risks and uncertainties associated with the development and/or approval of Hansa Biopharma's product candidates; ongoing clinical trials and expected trial results; the ability to commercialize imlifidase if approved; changes in legal or regulatory frameworks, requirements, or standards; technology changes and new products in Hansa Biopharma's potential market and industry; the ability to develop new products and enhance existing products; the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

The factors set forth above are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment, and it is not possible to predict all factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Hansa Biopharma expressly disclaims any obligation to update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or otherwise, and disclaims any express or implied representations or warranties that may arise from any forward-looking statements. You should not rely upon these forward-looking statements after the date of this presentation.

HANSA BIOPHARMA

Pierre-Henri Patin M.D
VP Commercial Europe Hansa Biopharma

MD degree from Paris Descartes University Paris, France
Mastere degree from ESCP Paris, France

≥20 years of Pharma Experience
With more than 15 years in Biotech International Leadership roles
- 5 years at Celgene with GM roles
- 9 years at Vertex International Regional VP

Joined Hansa Biopharma december 2020

HANSA BIOPHARMA

Many milestones achieved during the last 15 months



Idefirix® (imlifidase) has received conditional approval in the European Union

Low complexity transplants ⟵ ⟶ Higher complexity transplants

~70% of patients[1,2]	15-20% of patients[1,2]	10-15% of patients[1,2]
Non or less sensitized (cPRA < 20%)	Moderately sensitized (20% < cPRA < 80%)	Highly sensitized (cPRA > 80%)
		Highly sensitized patients that are likely to be transplanted with a compatible donor
		Highly sensitized patients unlikely to be transplanted under available KAS, including prioritization programs

Actual patient has given consent to provide images

Idefirix® is indicated for

desensitization treatment of highly sensitized adult kidney transplant patients with positive crossmatch against an available deceased donor.

The use of Idefirix® should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritization programs for highly sensitized patients

Potential patients

idefirix® imlifidase

HANSA BIOPHARMA

[1] EDQM. (2020). International figures on donation and Transplantation 2019
[2] SRTR Database and individual assessments of allocation systems

The kidney transplantation landscape in Europe and the U.S.

Up to 15% of patients waiting for a new kidney are highly sensitized

Breakdown of the kidney transplant waitlist in U.S. and EU



Source: The U.S. Department of Health and Human Services and .irodat.org

~50,000 transplants done annually in the U.S. and Europe



Source: Global Observatory on Donation and Transplantation, http://www.transplant-observatory.org/

*Reported to be impacted by the COVID-19 pandemic

Market access has now been secured in nine European countries and procedures are ongoing in nine countries including Spain, Italy and Belgium



[1]Annual kidney transplantations 2019 (pre-Corona)
*Transplantation data is from Global Observatory on Donation and Transplantation, 2019
**Pricing & reimbursement obtained in France on an early access basis

The European Society for Organ Transplantation's (ESOT) guidelines for desensitization treatment of highly sensitized patients published in *Transplant International* in August 2022

Guidelines represent first international consensus on a management pathway for highly sensitized patients

- The European guidelines document is a result of an expert working group, led by Professor Nizam Mamode M.D. Professor of Transplant Surgery, previously at Guys and St Thomas Hospital, London, and supported by other leading experts in the transplantation field.[1]
- Guidelines include imlifidase and provide a new clinical practice tool for healthcare professionals and represent the first international consensus on a management pathway for highly sensitized patients.
- Guidelines articulate the variability in definitions, approaches, outcomes as well as the perceived success of HLA-related transplantations
- Hansa Biopharma sponsors desensitization workstream as part of ESOT's educational programs, via an educational grant

Transplant International

https://www.frontierspartnerships.org/articles/10.3389/ti.2022.10511/full


GUIDELINES
published: 10 August 2022
doi: 10.3389/ti.2022.10511

ESOT | Transplant International

European Guideline for the Management of Kidney Transplant Patients With HLA Antibodies: By the European Society for Organ Transplantation Working Group

Nizam Mamode[1]*, Oriol Bestard[2], Frans Claas[3,4], Lucrezia Furian[5], Siân Griffin[6], Christophe Legendre[7], Liset Pengel[8] and Maarten Naesens[9]

[1]Department of Transplantation, Guys Hospital, London, United Kingdom, [2]Department of Nephrology and Kidney Transplantation, Vall d'Hebron University Hospital, Barcelona, Spain, [3]Department of Immunology, Leiden University Medical Center, Leiden, Netherlands, [4]Department of Surgical Gastroenterological and Oncological Sciences, University Hospital of Padua, Padua, Italy, [5]Department of Nephrology, University Hospital of Wales, Cardiff, United Kingdom, [6]Centre for Evidence in Transplantation, University of Oxford, Oxford, United Kingdom, [7]Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium

This guideline, from a European Society of Organ Transplantation (ESOT) working group, concerns the management of kidney transplant patients with HLA antibodies. Sensitization should be defined using a virtual parameter such as calculated Reaction Frequency (cRF), which assesses HLA antibodies derived from the actual organ donor population. Highly sensitized patients should be prioritized in kidney allocation schemes and linking allocation schemes may increase opportunities. The use of the ENGAGE 5 ((Bestard et al., Transpl Int, 2021, 34: 1005–1018) system and online calculators for assessing risk is recommended. The Eurotransplant Mismatch program should be considered. If strategies for finding a compatible kidney are very unlikely to yield a extended, desensitization may be considered and should be performed with plasma ...adsorption, supplemented with MG and/or anti-CD20 antibody. ...idase, may offer alternatives. Few studies compare HLA ...on the waiting list, and comparisons of ...change programs (KEP) should ...donors, as well as ...highly

OPEN ACCESS

*Correspondence: Nizam Mamode

[1]Mamode N, Bestard O, Claas F, Furian L, Griffin S, Legendre C, Pengel L and Naesens M (2022) European Guideline for the Management of Kidney Transplant Patients With HLA Antibodies: By the European Society for Organ Transplantation Working Group. Transpl Int 35:10511. doi: 10.3389/ti.2022.10511

Our center focused and sequenced launch process will help build the foundation for Idefirix® to become a new Standard of Care in transplantation

Idefirix® is the first and only approved treatment in Europe for desensitization treatment of highly sensitized kidney transplant patients. The long-term market uptake is highly dependent on successful early experiences in key early adopter centers

Illustrative

1 Build the foundation for Idefirix® in EU to become a new Standard of Care

- Commercialize in early-launch countries focusing on leading clinics and early adopters
- Secure Pricing and Reimbursement agreements
- Ensure clinical readiness and KOL engagement
- Implement new medical guidelines through ESOT
- Increase awareness on unmet need through KOL engagement, patient organizations and medical conferences
- Initiate post approval study in Europe to support full approval and establish long-term outcomes

2 Expanding internationally will lead to more accelerated growth mid term

- Leverage experience to scale Idefirix in Europe with early-launch centers and in the five largest markets after completing market access
- Launch in the U.S. following completion of the ConfIdeS study and FDA approval
- Expand to select markets and regions beyond core markets in EU and the U.S. through partnerships
- Full marketing authorization in Europe
- Support patient and organ access for highly sensitized patients

3 Potential label expansion will enable new growth pockets longer term

- Commercialize in AMR in kidney upon potential approval
- Potentially expand into living donor transplantation
- Potentially expand into other solid organ transplantations such as heart and lung pre- and post transplantation (AMR)



HANSA BIOPHARMA

Total Revenue amounted to SEK 67m in the third quarter including SEK 23m in product sales






HANSA
BIOPHARMA